

# **Our Ion Channel Laboratory**

# Rapid, High Quality Ion Channel Profiling Matched to Your Design-Make-Test Cycle

Whether you need to explore cardiac ion channel activity for safety, or are interested in ion channels as drug targets, ApconiX can help with our dedicated electrophysiology expertise, customer focused flexibility and rapid turnaround times.

Our nonclinical safety experts are uniquely positioned to work with your project team to interpret your data in the context of your drug discovery programme.

### **Our Services Include:**

- Ion channel screening for hERG, cardiac and neuro liabilities, and all elements of the CiPA paradigm
  including the ion channel panel (hERG, hNav1.5 peak and late current, hKvLQT1, hKv4.3, hCaV1.2, hKir2.1),
  in silico action potential modelling, and investigation in the hiPSC-cardiomyocytes
- Bespoke assay development
- Direct, functional electrophysiology measurements, performed by experts, with fewer artefacts than ligand-binding or fluorescence assays
- Testing on the latest generation automated electrophysiology platforms with the capacity for large numbers of compounds
- Access to ApconiX scientists who will tailor our service specifically to your needs and better advise you on your next steps
- Over 80% of data are returned to clients within one week

"Your data turnaround time is incredibly good, and it really helps us to track SAR and progress our compounds in a rapid and efficient manner. Thanks ApconiX for your wonderful support to Bugworks."

Ion channels play a central role in normal and disease biology. ApconiX develop and optimise novel ion channel assays for hit identification, selectivity profiling or mechanism of action studies.

## **Examples of Bespoke Assay Development**

#### Hit Identification/HTS

We have developed a dual addition protocol in 384-well format for the high-throughput screening (HTS) of ~10,000 compounds against an epithelial sodium channel isoform by automated electrophysiology.





#### **Selectivity Profiling**

We are often asked to define the selectivity profile of compounds against a bespoke panel of ion channel targets. Each panel is specific to the client's needs and the selectivity they are trying to demonstrate.

#### **Bepsoke Investigations**

Whether we are testing pharmaceuticals or agrochemicals, we are happy to carry out bespoke investigations to help you optimise your discovery programme. For example we have investigated the effect of impurities, compound solubility, new modalities including antibodies, peptides and aptamers for clients.



Contact the ApconiX team for more details

# ApconiX is a team of nonclinical safety experts providing drug discovery and development support in toxicology and electrophysiology.

#### **Meet Some of the Team**



**Dr Michael Morton** 

A co-founder of ApconiX, Dr Michael Morton is an expert electrophysiologist and ion channel biologist. Mike has a serious passion for ion channels and works with collaborators and clients alike to ensure the highest quality data are used to support better decision-making.



**Dr Kimberly Rockley** 

Dr Kimberly Rockley carried out her post graduate research at Durham University in anthracycline-induced cardiotoxicity and its mitigation by angiotensin blockade in vitro. Kim studied for a BSc in Biomedical Science and Master's degree in Cancer Pharmacology at the University of Bradford. Currently Kim is investigating the ion channels implicated in seizure.



**Dr Karen Jones** 

Dr Karen Jones has over 10 years experience in the pharmaceutical industry within the early drug discovery setting. Karen's area of expertise is in the development of ion channel and GPCR assays which are used for compound screening in various formats from small scale bespoke experiments up to large scale fully automated screens.

Contact the ApconiX team for more details